- Home
- OMAB vs VKTX Comparison
OMAB vs VKTX Comparison
Compare OMAB & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMAB
- VKTX
- Stock Information
- Founded
- OMAB 1998
- VKTX 2012
- Country
- OMAB Mexico
- VKTX United States
- Employees
- OMAB N/A
- VKTX N/A
- Industry
- OMAB Aerospace
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- OMAB Consumer Discretionary
- VKTX Health Care
- Exchange
- OMAB Nasdaq
- VKTX Nasdaq
- Market Cap
- OMAB 3.7B
- VKTX 3.4B
- IPO Year
- OMAB 2006
- VKTX 2015
- Fundamental
- Price
- OMAB $79.89
- VKTX $34.07
- Analyst Decision
- OMAB Buy
- VKTX Strong Buy
- Analyst Count
- OMAB 2
- VKTX 14
- Target Price
- OMAB $99.00
- VKTX $97.29
- AVG Volume (30 Days)
- OMAB 74.8K
- VKTX 4.8M
- Earning Date
- OMAB 02-25-2025
- VKTX 02-05-2025
- Dividend Yield
- OMAB 5.91%
- VKTX N/A
- EPS Growth
- OMAB 2.12
- VKTX N/A
- EPS
- OMAB 0.66
- VKTX N/A
- Revenue
- OMAB $748,989,666.00
- VKTX N/A
- Revenue This Year
- OMAB N/A
- VKTX N/A
- Revenue Next Year
- OMAB $6.87
- VKTX $986.87
- P/E Ratio
- OMAB $15.68
- VKTX N/A
- Revenue Growth
- OMAB 1.76
- VKTX N/A
- 52 Week Low
- OMAB $59.08
- VKTX $28.64
- 52 Week High
- OMAB $90.53
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- OMAB 54.57
- VKTX 51.41
- Support Level
- OMAB $79.50
- VKTX $28.90
- Resistance Level
- OMAB $83.69
- VKTX $34.37
- Average True Range (ATR)
- OMAB 2.66
- VKTX 2.37
- MACD
- OMAB 0.04
- VKTX 0.66
- Stochastic Oscillator
- OMAB 64.45
- VKTX 70.06
About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS
Grupo Aeroportuario del Centro Norte SAB de CV operates airports in the central region of Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages two hotels and one industrial park.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.